What did the August 2026 FDA peptide warning letters say?

FDA said five online sellers marketed cited products as unapproved new drugs and misbranded drugs. The agency relied on the websites’ health claims, preparation supplies, guides, and other context as evidence that the products were intended for use by people. The letters were issued August 24, 2026, and posted September 1.

Does a laboratory-use label make an online peptide legal to sell to people?

No. FDA’s August letters show that the agency looks beyond one line on a label. Health claims, preparation guidance, calculators, and water sold to mix an injectable can all help show intended human use. A scientific-looking disclaimer also says nothing by itself about the vial’s identity, strength, sterility, or dispensing source.

Did the letters prohibit tirzepatide, PT-141, or tesamorelin?

No. The letters are notices to five named sellers about specific products and marketing practices. They are not a molecule-wide rule, recall, or final agency action. A licensed provider may still prescribe a compounded formulation when applicable compounding requirements are met and the provider decides it is appropriate for an individual patient.

Are FDA warning letters the same as recalls?

No. A warning letter communicates FDA’s position and asks a firm to correct significant concerns or explain why it disagrees. FDA describes these letters as informal, advisory notices rather than final agency action. A recall is a separate step involving removal or correction of a product in commerce; these five letters did not announce recalls.

How is a prescribed compounded peptide different from an online seller’s vial?

The prescription route ties the medication to an identified patient, a licensed prescriber, and a dispensing pharmacy. Under section 503A, a valid patient-specific prescription is one condition for the federal compounding exemptions. That accountability does not turn a compounded preparation into a branded product, but it gives the patient a clinician and pharmacy of record.

FDA Peptide Warning Letters: What They Mean

The FDA peptide warning letters sent to five online sellers make one thing clear: calling an injectable peptide a laboratory product does not settle how the law treats it. FDA looked at what the websites said the products could do, what they sold alongside the vials, and whether the whole setup pointed to use by people.

The letters do not prohibit peptides as a class. They are company-specific notices about products FDA said were being marketed as unapproved new drugs and misbranded drugs, meaning the agency said the products lacked required approval and labeling.

As of September 6, 2026, the day this article was written, the five letters were dated August 24 and posted September 1, and a search of the Federal Register showed no peptide-specific proposed or final rule issued in response.

What the FDA peptide warning letters said

FDA’s Center for Drug Evaluation and Research sent the letters to Peak Performance Peptides, Peptide Partners LLC, NuScience Peptides, Royal Peptides, and TXP Innovations LLC, doing business as Tex Peptides. FDA’s warning-letter index lists all five under “Unapproved New Drugs/Misbranded.”

The products varied by site. Across the letters, FDA named semaglutide, tirzepatide, retatrutide, survodutide, mazdutide, SS-31, PT-141, tesamorelin, and a tesamorelin/ipamorelin blend, along with water sold to prepare injections.

The Peak Performance letter, Peptide Partners letter, and NuScience letter each say the agency reviewed the sellers’ websites in July 2026. The letters gave the recipients 15 business days to explain corrective steps or provide information showing why they disagreed.

A warning letter is serious, but it is not a court judgment or a recall. FDA’s 2026 investigations manual calls warning letters informal and advisory. They state the agency’s position and may lead to enforcement if the concerns are not corrected, but they are not final agency action.

Why the laboratory label did not decide the issue

The load-bearing part of the letters is about intended use—what the seller’s words and conduct show a product is meant to do. FDA said the sites presented the peptides with claims about weight, blood sugar, sexual function, body composition, and other effects in people. Several also sold bacteriostatic water, a sterile mixing liquid, beside the vials. One offered a peptide guide and calculator.

In that context, FDA said labeling the products for laboratory use did not outweigh the rest of the evidence. The agency treated each website as a whole, not the disclaimer as a magic sentence that erased everything around it.

That is the practical lesson for someone looking at a polished peptide storefront. Scientific language, a purity percentage, and a laboratory label do not establish that the vial came through a pharmacy, was prepared for an identified patient, or was checked within a clinical relationship.

What this means before buying a vial online

A website can look careful and still leave the most important questions unanswered: Who made the product? Who is legally responsible for dispensing it? Was its identity and strength checked? Which clinician reviewed whether it fits the person receiving it?

The quality concern is not theoretical. In a 2024 Journal of Medical Internet Research study, researchers tried to buy semaglutide from six illegal online pharmacies. Three vials arrived. All three contained about 29% to 39% more semaglutide than their labels claimed, and all contained endotoxin, a residue from bacterial cell walls.

A 2018 Talanta laboratory study examined ten kinds of falsified peptide drugs obtained from three suspected illegal internet pharmacies. The researchers found wide variation in content, peptide impurities, and toxic elemental contaminants including lead and inorganic arsenic; some measurements reached up to ten times the accepted injection limit. These were not the products in the 2026 letters, but the findings show why a web page’s claims cannot substitute for an accountable supply chain.

The letters named PT-141, but they did not report a new clinical safety finding about PT-141 itself. Their concern was how specific online products were presented and sold.

What the letters do not mean

They do not create one new rule for every peptide. They do not prove that every vial sold online has the wrong contents. And they do not announce that tirzepatide, PT-141, or tesamorelin has become unavailable through every medical route.

They also do not settle each molecule’s full legal or regulatory story. Are peptides legal? covers that broader question. For one molecule-specific example, see why a compounded tirzepatide preparation is not FDA-approved.

A licensed provider may still prescribe a compounded formulation when applicable compounding rules are met; that decision is between the patient and the doctor. At Promise, tirzepatide is dispensed as a compounded medication, which is different from an FDA-approved product: the formulation offered here is not FDA-approved.

How the prescription route is different

Federal law gives patient-specific compounding its own lane. Under section 503A, a state-licensed pharmacy or licensed physician may qualify for specific exemptions when the medication is compounded for an identified patient from a valid prescription and the other statutory conditions are met. FDA explains those basics in its human drug compounding laws.

That does not make a compounded preparation the same as a branded drug, and it does not mean every compounded option fits every patient. It means there is a prescriber, a prescription, a dispensing pharmacy, and a record tying the medication to one person. How compounded medications are made explains what happens after the prescription reaches the pharmacy.

At Promise, a licensed provider reviews every request and not everyone qualifies. A first-time patient can also check a telehealth doctor’s state license instead of taking a website’s word for it.

Tesamorelin appeared in all three detailed letters above. Its presence there says something about those sellers’ product pages, not that a clinician can skip the normal questions about medical fit, formulation, and pharmacy source.

What to watch next

The next useful signals are concrete ones: responses or closeout letters added to FDA’s warning-letter pages, more letters from the same office, or an actual notice or rule in the Federal Register document database. A seller quietly changing a page is not the same as FDA closing a matter.

For a patient, the steady question is simpler. If a product is meant to be injected by a person, who reviewed the person, who dispensed the product, and who is accountable if something goes wrong?